Provided by Tiger Trade Technology Pte. Ltd.

Madrigal Pharmaceuticals

499.40
-0.3100-0.06%
Post-market: 499.400.00000.00%19:30 EDT
Volume:289.23K
Turnover:143.75M
Market Cap:11.51B
PE:-35.13
High:505.00
Open:505.00
Low:491.05
Close:499.71
52wk High:615.00
52wk Low:393.61
Shares:23.06M
Float Shares:13.73M
Volume Ratio:1.24
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.2164
EPS(LYR):-12.8501
ROE:-53.31%
ROA:-17.84%
PB:21.98
PE(LYR):-38.86

Loading ...

Madrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL

TIPRANKS
·
Aug 14

Madrigal Pharmaceuticals Adds Renowned Leader to Board

TIPRANKS
·
Aug 12

Madrigal Appoints J&J R&D Chief John Reed to Board

Reuters
·
Aug 12

Madrigal Appoints John C. Reed, M.d., Ph.d., to Its Board of Directors

THOMSON REUTERS
·
Aug 12

Press Release: Madrigal Appoints John C. Reed, M.D., Ph.D., to Its Board of Directors

Dow Jones
·
Aug 12

Madrigal Pharmaceuticals Grants 4,263 Inducement RSUs to 10 New Employees

Reuters
·
Aug 07

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 07

Madrigal Pharmaceuticals to Present at Canaccord Genuity Annual Growth Conference

Reuters
·
Aug 06

Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth

Reuters
·
Aug 05

Madrigal upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
Aug 04

Madrigal Pharmaceuticals is Maintained at Overweight by Barclays

Dow Jones
·
Aug 03

Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays

TIPRANKS
·
Aug 03

Movement Alert|Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure

Market Focus
·
Jul 31

Madrigal Pharmaceuticals Inc : Bofa Global Research Cuts Price Objective to $543 from $553

THOMSON REUTERS
·
Jul 31

Neurocrine Biosciences Q2 Adjusted EPS Beats Expectations, Revenue Rises on Product Portfolio Growth

Reuters
·
Jul 31

Madrigal Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Movement Alert|Madrigal Pharmaceuticals Falls 12.78% in Regular Trading, Q2 Revenue Beats Expectations but Year-over-Year Loss Widens

Market Focus
·
Jul 30

Stock Track | Madrigal Pharmaceuticals Plummets 7.56% in Pre-market as Q2 Loss Widens and Expenses Surge Despite Revenue Beat

Stock Track
·
Jul 30

Movement Alert|Madrigal Pharmaceuticals Falls 6.74% in Pre-Market Trading, Q2 Earnings Beat Estimates but Per-Share Loss Widens Year-Over-Year

Market Focus
·
Jul 30

Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra

Reuters
·
Jul 30